open access

Vol 79, No 3 (2021)
Expert opinion
Published online: 2021-03-04
Get Citation

Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction

Jadwiga Nessler, Aleksander Siniarski, Przemysław Leszek, Janusz Gumprecht, Jarosław Drożdż, Jarosław Kaźmierczak, Adam Witkowski, Andrzej Gackowski, Ewa A. Jankowska, Tomasz Kukulski, Małgorzata Lelonek, Piotr Rozentryt, Paweł Rubiś, Piotr Ponikowski
DOI: 10.33963/KP.15859
·
Pubmed: 33687868
·
Kardiol Pol 2021;79(3):363-370.

open access

Vol 79, No 3 (2021)
Expert opinion and position paper
Published online: 2021-03-04

Abstract

ABSTRACT Heart failure (HF) is a global health problem inherent in an aging population with coexisting cardiovascular diseases. Based on data from the Polish National Health Fund (Polish, Narodowy Fundusz Zdrowia), approximately 1.2 million people in Poland currently suffer from HF, and 140 000 of them die annually. Recently, Poland was ranked fifth among the European Union countries regarding the number of patients with diagnosed HF and first in terms of the number of HF hospitalizations (547 per 100 000 population) among 34 countries associated in the Organization for Economic Cooperation and Development. In recent years, a significant progress has been made in the diagnosis and treatment of HF with reduced left ventricular ejection fraction (HFrEF), which has resulted in a reduction in cardiovascular and total mortality. Despite these advantages, 5-year survival in the course of HF is still worse than that observed in some types of cancer, both in the populations of men and women. Hence, the search for drugs improving the prognosis in this group of patients is still ongoing. Sodium-glucose cotransporter 2 inhibitors represent a new group of drugs that will undoubtedly be a milestone in the treatment of patients with HFrEF. This expert opinion covers the history of dapagliflozin, which, from a drug dedicated to the treatment of type 2 diabetes, has become one of the most effective drugs improving prognosis and quality of life as well as reducing the number of hospitalizations in patients with HF. This document presents the opinion from the experts of the Heart Failure Working Group of the Polish Cardiac Society on the most relevant studies on dapagliflozin and indications for its use.

Abstract

ABSTRACT Heart failure (HF) is a global health problem inherent in an aging population with coexisting cardiovascular diseases. Based on data from the Polish National Health Fund (Polish, Narodowy Fundusz Zdrowia), approximately 1.2 million people in Poland currently suffer from HF, and 140 000 of them die annually. Recently, Poland was ranked fifth among the European Union countries regarding the number of patients with diagnosed HF and first in terms of the number of HF hospitalizations (547 per 100 000 population) among 34 countries associated in the Organization for Economic Cooperation and Development. In recent years, a significant progress has been made in the diagnosis and treatment of HF with reduced left ventricular ejection fraction (HFrEF), which has resulted in a reduction in cardiovascular and total mortality. Despite these advantages, 5-year survival in the course of HF is still worse than that observed in some types of cancer, both in the populations of men and women. Hence, the search for drugs improving the prognosis in this group of patients is still ongoing. Sodium-glucose cotransporter 2 inhibitors represent a new group of drugs that will undoubtedly be a milestone in the treatment of patients with HFrEF. This expert opinion covers the history of dapagliflozin, which, from a drug dedicated to the treatment of type 2 diabetes, has become one of the most effective drugs improving prognosis and quality of life as well as reducing the number of hospitalizations in patients with HF. This document presents the opinion from the experts of the Heart Failure Working Group of the Polish Cardiac Society on the most relevant studies on dapagliflozin and indications for its use.
Get Citation
Supp./Additional Files (1)
Supplementary file 1
Download
610KB
About this article
Title

Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 79, No 3 (2021)

Article type

Expert opinion

Pages

363-370

Published online

2021-03-04

DOI

10.33963/KP.15859

Pubmed

33687868

Bibliographic record

Kardiol Pol 2021;79(3):363-370.

Authors

Jadwiga Nessler
Aleksander Siniarski
Przemysław Leszek
Janusz Gumprecht
Jarosław Drożdż
Jarosław Kaźmierczak
Adam Witkowski
Andrzej Gackowski
Ewa A. Jankowska
Tomasz Kukulski
Małgorzata Lelonek
Piotr Rozentryt
Paweł Rubiś
Piotr Ponikowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl